JP2019528316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528316A5 JP2019528316A5 JP2019530539A JP2019530539A JP2019528316A5 JP 2019528316 A5 JP2019528316 A5 JP 2019528316A5 JP 2019530539 A JP2019530539 A JP 2019530539A JP 2019530539 A JP2019530539 A JP 2019530539A JP 2019528316 A5 JP2019528316 A5 JP 2019528316A5
- Authority
- JP
- Japan
- Prior art keywords
- inhalation
- combination
- pharmaceutical aerosol
- fixed
- aerosol formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008249 pharmaceutical aerosol Substances 0.000 claims description 21
- 238000009472 formulation Methods 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 235000017274 Diospyros sandwicensis Nutrition 0.000 claims description 14
- 241000282838 Lama Species 0.000 claims description 14
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 claims description 14
- 238000002664 inhalation therapy Methods 0.000 claims description 13
- 230000005713 exacerbation Effects 0.000 claims description 12
- 229960002462 glycopyrronium bromide Drugs 0.000 claims description 12
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 claims description 10
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 10
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 10
- 229940125389 long-acting beta agonist Drugs 0.000 claims description 10
- ANGKOCUUWGHLCE-UHFFFAOYSA-N 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester Chemical compound C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-UHFFFAOYSA-N 0.000 claims description 8
- 229960002848 formoterol Drugs 0.000 claims description 8
- 150000005828 hydrofluoroalkanes Chemical class 0.000 claims description 8
- 230000000052 comparative effect Effects 0.000 claims description 7
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 6
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims description 6
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 6
- 229960004436 budesonide Drugs 0.000 claims description 6
- 229960002714 fluticasone Drugs 0.000 claims description 6
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 6
- 229960004017 salmeterol Drugs 0.000 claims description 6
- 229940110309 tiotropium Drugs 0.000 claims description 6
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 6
- 229960000257 tiotropium bromide Drugs 0.000 claims description 6
- -1 Glycopyrronium bromium Chemical class 0.000 claims description 5
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims description 4
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 229940000425 combination drug Drugs 0.000 claims description 4
- 239000006184 cosolvent Substances 0.000 claims description 4
- 150000004683 dihydrates Chemical class 0.000 claims description 4
- 229960000193 formoterol fumarate Drugs 0.000 claims description 4
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 claims description 4
- 229960004078 indacaterol Drugs 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003380 propellant Substances 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- DQHNAVOVODVIMG-RGECMCKFSA-M spiriva Chemical compound [Br-].C([C@@H]1[N+]([C@H](C2)[C@@H]3[C@H]1O3)(C)C)C2OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-RGECMCKFSA-M 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 2
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 2
- 229940092705 beclomethasone Drugs 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 2
- 229960003728 ciclesonide Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16184608 | 2016-08-17 | ||
| EP16184608.4 | 2016-08-17 | ||
| PCT/EP2017/070850 WO2018033598A1 (en) | 2016-08-17 | 2017-08-17 | Combination therapy for copd |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528316A JP2019528316A (ja) | 2019-10-10 |
| JP2019528316A5 true JP2019528316A5 (cg-RX-API-DMAC7.html) | 2020-10-01 |
| JP7384666B2 JP7384666B2 (ja) | 2023-11-21 |
Family
ID=56740118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019530539A Active JP7384666B2 (ja) | 2016-08-17 | 2017-08-17 | Ｃｏｐｄに対する組合せ療法 |
Country Status (30)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| EA027778B1 (ru) | 2009-12-23 | 2017-08-31 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Комбинированная терапия copd |
| US10098837B2 (en) | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
| CN112438966B (zh) * | 2019-08-30 | 2022-08-26 | 四川普锐特药业有限公司 | 一种医用定量吸入气雾剂 |
| CN114502146A (zh) * | 2019-12-02 | 2022-05-13 | 奇斯药制品公司 | 用于加压定量吸入器的不锈钢罐 |
| CN115003282A (zh) * | 2020-01-28 | 2022-09-02 | 奇斯药制品公司 | 包含缓冲药物制剂的加压定量吸入器 |
| AU2021223587A1 (en) * | 2020-02-20 | 2022-09-29 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| AU2021314977B2 (en) * | 2020-07-31 | 2025-03-13 | Chemo Research, S.L. | Combination therapy for inhalation administration |
| JP2023546025A (ja) * | 2020-10-09 | 2023-11-01 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 加圧定量吸入器のための医薬製剤 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| IT1317720B1 (it) | 2000-01-07 | 2003-07-15 | Chiesi Farma Spa | Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani. |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| HRP20021025B1 (hr) | 2000-05-22 | 2013-11-22 | Chiesi Farmaceutici S.P.A. | Formulacije stabilnih farmaceutskih otopina za inhalatore s odmjerenom dozom pod tlakom |
| EP1321159A1 (en) | 2001-12-21 | 2003-06-25 | CHIESI FARMACEUTICI S.p.A. | Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices |
| PL1713473T3 (pl) | 2004-02-06 | 2013-08-30 | Meda Pharma Gmbh & Co Kg | Kombinacja leków antycholinergicznych i glikokortykoidów do długotrwałego leczenia astmy i POChP |
| GB0410399D0 (en) | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| EP2484382A1 (en) | 2005-03-30 | 2012-08-08 | Schering Corporation | Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form |
| GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| EA027778B1 (ru) * | 2009-12-23 | 2017-08-31 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Комбинированная терапия copd |
| KR20150048727A (ko) | 2012-08-29 | 2015-05-07 | 키에시 파르마슈티시 엣스. 피. 에이. | 에어로졸 흡입 장치 |
| BR112015028964A2 (pt) | 2013-05-22 | 2017-07-25 | Pearl Therapeutics Inc | composição de suspensão, e, método para tratar uma doença ou um distúrbio pulmonar |
| KR101861117B1 (ko) * | 2013-12-30 | 2018-05-28 | 키에시 파르마슈티시 엣스. 피. 에이. | 글리코피로니움 브로마이드 및 포모테롤 조합의 안정한 가압 에어로졸 용액 조성물 |
| CN105848642A (zh) | 2013-12-30 | 2016-08-10 | 奇斯药制品公司 | 格隆溴铵和福莫特罗组合的稳定的加压气雾剂溶液组合物 |
| US10098837B2 (en) | 2016-07-28 | 2018-10-16 | Chiesi Farmaceutici S.P.A. | Combination therapy for COPD |
-
2017
- 2017-07-28 US US15/663,364 patent/US10098837B2/en active Active
- 2017-08-17 MD MDE20190710T patent/MD3500241T2/ro unknown
- 2017-08-17 EP EP17758473.7A patent/EP3500241B1/en active Active
- 2017-08-17 CA CA3029481A patent/CA3029481A1/en active Pending
- 2017-08-17 LT LTEPPCT/EP2017/070850T patent/LT3500241T/lt unknown
- 2017-08-17 ES ES17758473T patent/ES2961242T3/es active Active
- 2017-08-17 MA MA45984A patent/MA45984B1/fr unknown
- 2017-08-17 PL PL17758473.7T patent/PL3500241T3/pl unknown
- 2017-08-17 UA UAA201902491A patent/UA123231C2/uk unknown
- 2017-08-17 WO PCT/EP2017/070850 patent/WO2018033598A1/en not_active Ceased
- 2017-08-17 EA EA201990514A patent/EA201990514A1/ru unknown
- 2017-08-17 GE GEAP201715023A patent/GEP20227418B/en unknown
- 2017-08-17 PT PT177584737T patent/PT3500241T/pt unknown
- 2017-08-17 MX MX2019001587A patent/MX395722B/es unknown
- 2017-08-17 BR BR112019003173A patent/BR112019003173A2/pt unknown
- 2017-08-17 AU AU2017314153A patent/AU2017314153B2/en active Active
- 2017-08-17 HU HUE17758473A patent/HUE064623T2/hu unknown
- 2017-08-17 RS RS20231015A patent/RS64751B1/sr unknown
- 2017-08-17 HR HRP20231729TT patent/HRP20231729T1/hr unknown
- 2017-08-17 NZ NZ750214A patent/NZ750214A/en unknown
- 2017-08-17 DK DK17758473.7T patent/DK3500241T3/da active
- 2017-08-17 JP JP2019530539A patent/JP7384666B2/ja active Active
- 2017-08-17 SI SI201731458T patent/SI3500241T1/sl unknown
- 2017-08-17 SG SG11201900471VA patent/SG11201900471VA/en unknown
- 2017-08-17 CN CN201780049986.3A patent/CN109562061A/zh active Pending
- 2017-08-17 FI FIEP17758473.7T patent/FI3500241T3/fi active
- 2017-08-17 KR KR1020197004574A patent/KR102440850B1/ko active Active
-
2019
- 2019-01-14 ZA ZA2019/00239A patent/ZA201900239B/en unknown
- 2019-02-03 IL IL264612A patent/IL264612B2/en unknown
- 2019-02-14 PH PH12019500315A patent/PH12019500315A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528316A5 (cg-RX-API-DMAC7.html) | ||
| FI3500241T3 (fi) | Yhdistelmähoito copd:lle | |
| AU2012216890A1 (en) | Combination of glycopyrrolate and a beta2 -agonist | |
| JP2018199684A5 (cg-RX-API-DMAC7.html) | ||
| IL143986A (en) | Combinations of formotrol and tiotropium salt | |
| NZ600790A (en) | Combination therapy for copd | |
| JP2013542940A5 (cg-RX-API-DMAC7.html) | ||
| JP2016041713A5 (cg-RX-API-DMAC7.html) | ||
| RU2019100425A (ru) | Новая доза и препаративная форма | |
| JP2010132695A5 (cg-RX-API-DMAC7.html) | ||
| CA2796934A1 (en) | Process for providing particles with reduced electrostatic charges | |
| NZ600789A (en) | Aerosol formulation for copd | |
| JP2007520508A5 (cg-RX-API-DMAC7.html) | ||
| JP2015519356A5 (cg-RX-API-DMAC7.html) | ||
| RU2015154720A (ru) | Композиции, способы и системы для респираторной доставки трех или более активных средств | |
| JP2020023536A (ja) | Ｃｏｐｄの治療のためのフォルモテロール及びブデソニドの組み合わせ | |
| PE20040326A1 (es) | Medicamento que contiene esteroides y un nuevo anticolinergico | |
| CN104955448A (zh) | 适用于吸入治疗的包含多组分结晶颗粒的药物组合物 | |
| US20130104881A1 (en) | Stabilized Metered Dose Inhaler | |
| HRP20140818T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
| US20180256561A1 (en) | Pharmaceutical Combination | |
| MX373699B (es) | Composicion farmaceutica que contiene budesonida y formoterol. | |
| KR20180101438A (ko) | 7-아조니아바이사이클로[2.2.1]헵탄 유도체의 건조 분말 흡입기 조성물 | |
| RU2013148786A (ru) | Улучшенный состав суспензии кортикостероида для ингаляционного введения | |
| MX2023001201A (es) | Terapia combinada para la administracion por inhalacion. |